Literature DB >> 18669614

Development and validation of human psoriatic skin equivalents.

Geuranne Tjabringa1, Mieke Bergers, Desiree van Rens, Roelie de Boer, Evert Lamme, Joost Schalkwijk.   

Abstract

Psoriasis is an inflammatory skin disease driven by aberrant interactions between the epithelium and the immune system. Anti-psoriatic drugs can therefore target either the keratinocytes or the immunocytes. Here we sought to develop an in vitro reconstructed skin model that would display the molecular characteristics of psoriatic epidermis in a controlled manner, allowing the screening of anti-psoriatic drugs and providing a model in which to study the biology of this disease. Human skin equivalents generated from normal human adult keratinocytes after air exposure and stimulation by keratinocyte growth factor and epidermal growth factor displayed the correct morphological and molecular characteristics of normal human epidermis whereas the psoriasis-associated proteins, hBD-2, SKALP/elafin, and CK16, were absent. Skin equivalents generated from foreskin keratinocytes were clearly abnormal both morphologically and with respect to gene expression. When normal skin equivalents derived from adult keratinocytes were stimulated with psoriasis-associated cytokines [tumor necrosis factor-alpha, interleukin (IL)-1alpha, IL-6, and IL-22] or combinations thereof, strong expression of hBD-2, SKALP/elafin, CK16, IL-8, and tumor necrosis factor-alpha was induced as shown by quantitative polymerase chain reaction and immunohistochemistry. Retinoic acid but not cyclosporin A was found to inhibit cytokine-induced gene expression at both the mRNA and protein levels. These results illustrate the potential of this disease model to study the molecular pathology and pharmacological intervention in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669614      PMCID: PMC2527086          DOI: 10.2353/ajpath.2008.080173

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  Cytokines in psoriasis.

Authors:  C Bonifati; F Ameglio
Journal:  Int J Dermatol       Date:  1999-04       Impact factor: 2.736

Review 2.  Psoriasis.

Authors:  Michael P Schön; W-Henning Boehncke
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

Review 3.  The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport.

Authors:  Frank Netzlaff; C-M Lehr; P W Wertz; U F Schaefer
Journal:  Eur J Pharm Biopharm       Date:  2005-07       Impact factor: 5.571

Review 4.  Psoriasis--recent advances in understanding its pathogenesis and treatment.

Authors:  Gerald Krueger; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2005-07       Impact factor: 11.527

5.  Induction of normal and psoriatic phenotypes in submerged keratinocyte cultures.

Authors:  F Van Ruissen; G J de Jongh; P L Zeeuwen; P E Van Erp; P Madsen; J Schalkwijk
Journal:  J Cell Physiol       Date:  1996-08       Impact factor: 6.384

Review 6.  Getting under the skin: the immunogenetics of psoriasis.

Authors:  Anne M Bowcock; James G Krueger
Journal:  Nat Rev Immunol       Date:  2005-09       Impact factor: 53.106

7.  In vitro reproduction of clinical hallmarks of eczematous dermatitis in organotypic skin models.

Authors:  Karin Engelhart; Tarek El Hindi; Hans-Konrad Biesalski; Inka Pfitzner
Journal:  Arch Dermatol Res       Date:  2005-06-11       Impact factor: 3.017

Review 8.  Psoriasis: emerging therapeutic strategies.

Authors:  Alice B Gottlieb
Journal:  Nat Rev Drug Discov       Date:  2005-01       Impact factor: 84.694

9.  Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis.

Authors:  S Nagpal; S M Thacher; S Patel; S Friant; M Malhotra; J Shafer; G Krasinski; A T Asano; M Teng; M Duvic; R A Chandraratna
Journal:  Cell Growth Differ       Date:  1996-12

10.  Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes.

Authors:  M Wingens; B H van Bergen; P S Hiemstra; J F Meis; I M van Vlijmen-Willems; P L Zeeuwen; J Mulder; H A Kramps; F van Ruissen; J Schalkwijk
Journal:  J Invest Dermatol       Date:  1998-12       Impact factor: 8.551

View more
  32 in total

1.  Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent.

Authors:  Marijke Kamsteeg; Mieke Bergers; Roelie de Boer; Patrick L J M Zeeuwen; Stanleyson V Hato; Joost Schalkwijk; Geuranne S Tjabringa
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases.

Authors:  Ellen H van den Bogaard; Geuranne S Tjabringa; Irma Joosten; Mieke Vonk-Bergers; Esther van Rijssen; Henk J Tijssen; Mirthe Erkens; Joost Schalkwijk; Hans J P M Koenen
Journal:  J Invest Dermatol       Date:  2013-10-11       Impact factor: 8.551

3.  Effects of reduced oxygen and glucose levels on ocular cells in vitro: implications for tissue models.

Authors:  Edward A Sander; Eric A Nauman
Journal:  Cells Tissues Organs       Date:  2009-07-28       Impact factor: 2.481

4.  Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models.

Authors:  Johann E Gudjonsson; Jun Ding; Andrew Johnston; Trilokraj Tejasvi; Andrew M Guzman; Rajan P Nair; John J Voorhees; Goncalo R Abecasis; James T Elder
Journal:  J Invest Dermatol       Date:  2010-03-11       Impact factor: 8.551

Review 5.  Human skin models: From healthy to disease-mimetic systems; characteristics and applications.

Authors:  Tânia Moniz; Sofia A Costa Lima; Salette Reis
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

Review 6.  Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications.

Authors:  Sana Suhail; Naseem Sardashti; Devina Jaiswal; Swetha Rudraiah; Manoj Misra; Sangamesh G Kumbar
Journal:  Biotechnol J       Date:  2019-05-17       Impact factor: 4.677

7.  A DNA methylation fingerprint of 1628 human samples.

Authors:  Agustin F Fernandez; Yassen Assenov; Jose Ignacio Martin-Subero; Balazs Balint; Reiner Siebert; Hiroaki Taniguchi; Hiroyuki Yamamoto; Manuel Hidalgo; Aik-Choon Tan; Oliver Galm; Isidre Ferrer; Montse Sanchez-Cespedes; Alberto Villanueva; Javier Carmona; Jose V Sanchez-Mut; Maria Berdasco; Victor Moreno; Gabriel Capella; David Monk; Esteban Ballestar; Santiago Ropero; Ramon Martinez; Marta Sanchez-Carbayo; Felipe Prosper; Xabier Agirre; Mario F Fraga; Osvaldo Graña; Luis Perez-Jurado; Jaume Mora; Susana Puig; Jaime Prat; Lina Badimon; Annibale A Puca; Stephen J Meltzer; Thomas Lengauer; John Bridgewater; Christoph Bock; Manel Esteller
Journal:  Genome Res       Date:  2011-05-25       Impact factor: 9.043

8.  Organotypic 3D Skin Models: Human Epidermal Equivalent Cultures from Primary Keratinocytes and Immortalized Keratinocyte Cell Lines.

Authors:  Gijs Rikken; Hanna Niehues; Ellen H van den Bogaard
Journal:  Methods Mol Biol       Date:  2020

9.  Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors:  Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.

Authors:  Ellen H van den Bogaard; Judith G M Bergboer; Mieke Vonk-Bergers; Ivonne M J J van Vlijmen-Willems; Stanleyson V Hato; Pieter G M van der Valk; Jens Michael Schröder; Irma Joosten; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.